Skip to content
10-K

Annual Report

LIGAND PHARMACEUTICALS INC LGND LGNDZ LGNXZ LGNYZ LGNZZ

0000886163-26-000006

← back to feed
Filed
Feb 27, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Feb 24, 2026 19.94M sh
Shares Diluted FY 2025 · Dec 31, 2025 20.29M sh
Shares Diluted FY 2025 · Dec 31, 2024 18.29M sh
Shares Diluted FY 2025 · Dec 31, 2023 17.76M sh
Stock Repurchased FY 2025 · Dec 31, 2025 $15M
Stock Repurchased FY 2025 · Dec 31, 2024 $0
Stock Repurchased FY 2025 · Dec 31, 2023 $0
Capex FY 2025 · Dec 31, 2025 $452K
Capex FY 2025 · Dec 31, 2024 $1.82M
Capex FY 2025 · Dec 31, 2023 $3.52M
Operating Cash Flow FY 2025 · Dec 31, 2025 $49.36M
Operating Cash Flow FY 2025 · Dec 31, 2024 $97.05M
Operating Cash Flow FY 2025 · Dec 31, 2023 $49.58M
Short Term Investments FY 2025 · Dec 31, 2025 $558.59M
Short Term Investments FY 2025 · Dec 31, 2024 $183.86M
Cash And Equivalents FY 2025 · Dec 31, 2025 $174.93M
Cash And Equivalents FY 2025 · Dec 31, 2024 $72.31M
Stockholders Equity FY 2025 · Dec 31, 2025 $1.02B
Stockholders Equity FY 2025 · Dec 31, 2024 $830.44M
Stockholders Equity FY 2025 · Dec 31, 2023 $700.91M
Stockholders Equity FY 2025 · Dec 31, 2022 $597.49M
Current Liabilities FY 2025 · Dec 31, 2025 $37.45M
Current Liabilities FY 2025 · Dec 31, 2024 $37.11M
Total Liabilities FY 2025 · Dec 31, 2025 $543.43M
Total Liabilities FY 2025 · Dec 31, 2024 $111.34M
Current Assets FY 2025 · Dec 31, 2025 $832.27M
Current Assets FY 2025 · Dec 31, 2024 $331.56M
Total Assets FY 2025 · Dec 31, 2025 $1.56B
Total Assets FY 2025 · Dec 31, 2024 $941.77M
Eps Diluted FY 2025 · Dec 31, 2025 $6.13
Eps Diluted FY 2025 · Dec 31, 2024 −$0.22
Eps Diluted FY 2025 · Dec 31, 2023 $2.94
Eps Basic FY 2025 · Dec 31, 2025 $6.44
Eps Basic FY 2025 · Dec 31, 2024 −$0.22
Eps Basic FY 2025 · Dec 31, 2023 $3.02
Sga Expense FY 2025 · Dec 31, 2025 $92.45M
Sga Expense FY 2025 · Dec 31, 2024 $78.65M
Sga Expense FY 2025 · Dec 31, 2023 $52.79M
Rd Expense FY 2025 · Dec 31, 2025 $81.18M
Rd Expense FY 2025 · Dec 31, 2024 $21.43M
Rd Expense FY 2025 · Dec 31, 2023 $24.54M
Net Income FY 2025 · Dec 31, 2025 $124.45M
Net Income FY 2025 · Dec 31, 2024 −$4.03M
Net Income FY 2025 · Dec 31, 2023 $52.15M
Operating Income FY 2025 · Dec 31, 2025 $41M
Operating Income FY 2025 · Dec 31, 2024 −$22.61M
Operating Income FY 2025 · Dec 31, 2023 $11.94M
Revenue FY 2025 · Dec 31, 2025 $268.09M
Revenue FY 2025 · Dec 31, 2024 $167.13M
Revenue FY 2025 · Dec 31, 2023 $131.31M